While reduction in cancer-specific mortality is the gold standard for surveillance tools, there is a pressing need to supplement mammography in high-risk women, particularly for BRCA1 and BRCA2 mutation carriers who are diagnosed with a high rate of interval tumors, roughly 50% [45]. The gene discussed is BRCA2; the disease is cancer.